Most Read Articles
21 Sep 2020
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.

Novel lipid-lowering drug halts development, progression of diabetes

07 Sep 2020

Bempedoic acid, a novel drug used to lower the bad cholesterol, reduces the risk of developing new-onset diabetes or its progression, according to the results of a meta-analysis.

Researchers searched multiple online databases for studies evaluating the effect of bempedoic acid therapy on new-onset or worsening diabetes with a minimum of 4 weeks of follow-up. They used the fixed-effects model and performed a meta-analysis according to PRISMA guidelines.

The meta-analysis included five randomized controlled trials of bempedoic acid. The total population comprised 3,629 patients, among whom 2,419 were allocated to receive bempedoic acid while 1,210 were allocated to the respective control arms.

Compared with control therapy, bempedoic acid was associated with a significant decrease in the risk of new-onset or worsening diabetes (odds ratio, 0.66, 95 percent confidence interval, 0.48–0.90; I2, 0 percent).

Additional investigation is warranted to confirm this finding.

Bempedoic acid is a small molecule inhibitor of ATP-citrate lyase, administered orally for the treatment of hyperlipidaemia. Its protective effect on diabetes risk may be related to AMP-activated protein kinase (AMPK), since bempedoic acid plays a dual role in both activation of hepatic AMPK signalling pathway and inhibitory activity against hepatic ATP-citrate lyase. [Curr Opin Lipidol 2014;25:309-315; J Lipid Res 2013;54:134-151]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Sep 2020
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.